Autocrine serotonin and transforming growth factor β1 signaling mediates spontaneous myxomatous mitral valve disease

Journal of Heart Valve Disease

Volumn 18, Issue 1, 2009, Pages 44-51

  Disatian, Sirilak ^a   Christopher Orton, E ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; SEROTONIN; SEROTONIN 2B RECEPTOR; SEROTONIN TRANSPORTER; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRYPTOPHAN HYDROXYLASE;

AGED; ANIMAL; ARTICLE; AUTOCRINE EFFECT; DOG; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MITRAL VALVE; VALVULAR HEART DISEASE;

AGED; ANIMALS; AUTOCRINE COMMUNICATION; DOGS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HEART VALVE DISEASES; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MITRAL VALVE; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; TRYPTOPHAN HYDROXYLASE;

EID: 65349154575     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Olsen LJ, Subramanian R, Ackermann DM, Orszulak TA, Edwards WD. Surgical pathology of the mitral valve: A study of 712 cases spanning 21 years. Mayo Clin Proc 1987;62:22-34 (Pubitemid 17232577)
2. Pedersen HD, Häggström J. Mitral valve prolapse in the dog: A model of mitral valve prolapse in man. Cardiovasc Res 2000;47:234-243 (Pubitemid 30625286)
3. Disatian S, Ehrhart EJ, Zimmerman S, Orton CE. Interstitial cells from dogs with naturally occurring myxomatous mitral valve disease undergo phenotype transformation. J Heart Valve Dis 2008;17:402-412
4. Rajamannan NM, Caplice N, Anthikad F, et al. Cell proliferation in carcinoid valve disease: A mechanism for serotonin effects. J Heart Valve Dis 2001;10:827-831 (Pubitemid 33133581)
5. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease: Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790-795
6. Veinot JP. Pathology of inflammatory native valvular heart disease. Cardiovasc Pathol 2006;15:243-251 (Pubitemid 44345235)
7. Gustafsson BI, Tommeras K, Nordrum I, et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005;111:1517-1522 (Pubitemid 40470647)
8. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588 (Pubitemid 27360757)
9. Rothman RB, Baumann MH. Therapeutic and adverse actions of serotonin transporter. Pharmacol Ther 2002;95:73-88
10. Ni W, Watts SW. 5-Hydroxytryptamine in the cardiovascular system: Focus on the serotonin transporter (SERT). Clin Exp Pharmacol Physiol 2006;33:575-583 (Pubitemid 43894017)
11. Mekontso-Dessap A, Brouri F, Pascal O, et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 2006;113:81-89 (Pubitemid 43958492)
12. Jian B, Xu J, Savani R, Narula N, Liang B, Levy RJ. Serotonin mechanisms in heart valve disease I: Serotonin induced upregulation of TGF-β1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 2002;161:2207-2216
13. Walker GA, Masters KS, Shah DN, Anseth KS, Leinwand LA. Valvular myofibroblast activation by transforming growth factor β: Implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res 2004;95:253-260 (Pubitemid 39056285)
14. Fox DJ, Khattar RS. Carcinoid heart disease: Presentation, diagnosis, and management. Heart 2004;90:1224-1228 (Pubitemid 39279919)
15. Simula DV, Edwards WD, Tazelaar HD, Connolly HM, Schaff HV. Surgical pathology of carcinoid heart disease: A study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc 2002;77:139-147 (Pubitemid 34118889)
16. Merocroft I, Dempsie Y, Bader M, et al. Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 2007;49:232-236 (Pubitemid 46360365)
17. Hoyer D, Fozard JR, Saxena PR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203 (Pubitemid 24185150)
18. Elangbam CS, Lightfoot RM, Yoon LW, et al. 5-Hydroxytryptamine (5HT) receptors in the heart valves of cynomolgus monkeys and Sprague-Dawley rats. J Histochem Cytochem 2005;53:671-677 (Pubitemid 40593980)
19. Roy A, Brand NJ, Yacoub MH. Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves. J Heart Valve Dis 2000;9:256-260
20. Nebigil CG, Launay JM, Hickel P, Tournois C, Maroteaux L. 5-Hydroxytryptamine 2B receptor regulates cell-cycle progression: Cross talk with tyrosine kinase pathways. Proc Natl Acad Sci USA 2000;97:2591-2596 (Pubitemid 30159215)
21. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-2841
22. Elangbam CS, Wehe JG, Barton JC, et al. Evaluation of glycosaminoglycans content and 5-hydroxytryptamine 2B receptor in the heart valves of Sprague-Dawley rats with spontaneous mitral valvulopathy: A possible exacerbation by dlamphetamine sulfate in Fischer 344 rats. Exp Toxicol Pathol 2006;58:89-99 (Pubitemid 44635158)
23. Oyama MA, Chittur SV. Genomic expression patterns of mitral valve tissues from dogs with degenerative mitral valve disease. Am J Vet Res 2006;67:1307-1318 (Pubitemid 44275484)
24. Launay JM, Schneider B, Loric S, Da Prada MD, Kellermann O. Serotonin transport and serotonin transporter-mediated antidepressant recognition are controlled by 5-HT2B receptor signaling in serotonergic neuronal cells. FASEB J 2006;20:1843-1854 (Pubitemid 44933798)
25. Elangbam CS, Job LE, Zadrozny LM, et al. 5-Hydroxytryptamine (5HT)-induced valvulopathy: Compositional valvular alteration are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol 2008;60:253-262
26. Cobb MH. MAP kinase pathways. Prog Biophys Mol Biol 1999;71:479-500 (Pubitemid 29156313)
27. Xu J, Jian B, Chu R, et al. Serotonin mechanisms in heart valve disease II: The 5-HT2 receptors and its signaling pathway in aortic valve interstitial cells. Am J Pathol 2002;161:2209-2218 (Pubitemid 35434865)
28. Crow T, Xue-Bian JJ, Siddiqi V, Neary JT. Serotonin activation of the ERK pathway in Hermissenda: Contribution of calcium-dependent protein kinase C. J Neurochem 2001;78:358-364 (Pubitemid 32664417)
29. Flaumenhaft R, Abe M, Sato Y, et al. Role of the latent TGF β binding protein in the activation of latent TGF β by co-culture of endothelial and smooth muscle cells. J Cell Biol 1993;120:995-1002 (Pubitemid 23056304)
30. Wrana JL. TGF β receptors and signaling mechanisms. Miner Electrolyte Metab 1998;24:120-130
31. Massague J, Cheifetz S, Laiho M, Ralph DA, Weis FM, Zentella A. Transforming growth factor β. Cancer Surg 1992;12:81-103
32. Grewel JS, Mukhin YV, Garnovskaya MN, Raymond JR, Greene EL. Serotonin 5-HT2A receptor induces TGF-β1 expression in mesangial cells via ERK: Proliferative and fibrotic signals. Am J Physiol 1999;276:F922-F930 (Pubitemid 29323566)